What if DNA contamination forces a recall of mRNA vaccine batches?
An mRNA DNA-contamination recall is an idiosyncratic platform-stock hit (Moderna/Pfizer/BioNTech), not a macro demand shock; sell the vaccine names and their CDMO suppliers, not crude. Rhymes with the 2022 J&J/AstraZeneca clotting halts and the 2023 Moderna guidance cuts, which gapped the equities ~15-30% while indices shrugged. The current pandemic-tagged oil-down cascade is spurious; cross-asset spillover is minimal beyond a token risk-appetite wobble.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 0–6 months horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. DNA-contamination findings force recall of mRNA vaccine batches, reigniting safety doubts and denting platform-stock valuations. The trigger decomposes into signed root‑shocks — Risk appetite ▼ — which propagate through our causal graph to the markets below.